Background Higher serum phosphate and fibroblast growth factor-23 (FGF23) levels may be
modifiable to prevent cardiovascular disease in CKD. Short-term studies have reported …

Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …

Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with
increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate …

Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering …

Background. High levels of fibroblast growth factor 23 (FGF23) are associated with mortality
and progression of chronic kidney disease (CKD). Reducing dietary phosphorus intake …

Phosphate is essential for life but its accumulation can be detrimental. In end‐stage renal
disease, widespread vascular calcification occurs as a result of chronic phosphate load. The …

Some propose using phosphate binders in the CKD population given the association
between higher levels of phosphorus and mortality, but their safety and efficacy in this …

Disturbances in phosphate homeostasis are common in patients with chronic kidney
disease. As kidney function declines, circulating concentrations of phosphate and the …

Background. In chronic kidney disease (CKD) patients, the ability to excrete a phosphate
load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast …

Background High fibroblast growth factor-23 (FGF-23) levels are associated with adverse
outcomes. We studied the responsiveness of FGF-23 and mineral metabolism to altered …